Private Wealth Partners LLC Sells 2,845 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Private Wealth Partners LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,358 shares of the medical research company's stock after selling 2,845 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.5% of Private Wealth Partners LLC's holdings, making the stock its 12th largest holding. Private Wealth Partners LLC's holdings in Thermo Fisher Scientific were worth $30,034,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $25,000. FPC Investment Advisory Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $28,000. Pillar Financial Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $29,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. Finally, Noble Wealth Management PBC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $35,000. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO opened at $392.54 on Friday. The company has a market capitalization of $148.18 billion, a price-to-earnings ratio of 23.02, a P/E/G ratio of 2.07 and a beta of 0.78. The business's 50-day moving average price is $413.43 and its two-hundred day moving average price is $488.79. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.11 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.44%. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent research reports. Scotiabank decreased their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. UBS Group cut their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Finally, The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $605.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.